专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US07202350B2 C-glycoside derivatives and salts thereof 有权
标题翻译： C-糖苷衍生物及其盐
公开(公告)号：US07202350B2
公开(公告)日：2007-04-10
申请号：US10541615
申请日：2004-03-12
申请人： Masakazu Imamura , Takeshi Murakami , Ryota Shiraki , Kazuhiro Ikegai , Takashi Sugane , Fumiyoshi Iwasaki , Eiji Kurosaki , Hiroshi Tomiyama , Atsushi Noda , Kayoko Kitta , Yoshinori Kobayashi
发明人： Masakazu Imamura , Takeshi Murakami , Ryota Shiraki , Kazuhiro Ikegai , Takashi Sugane , Fumiyoshi Iwasaki , Eiji Kurosaki , Hiroshi Tomiyama , Atsushi Noda , Kayoko Kitta , Yoshinori Kobayashi
IPC分类号： C07H1/00 , A61K31/70 , C07H7/06
CPC分类号： C07D495/04 , A61K31/351 , A61K31/381 , A61K31/4035 , A61K31/404 , A61K31/41 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/4433 , A61K31/497 , A61K31/5377 , C07D405/10 , C07D407/10 , C07D409/10 , C07D413/10 , C07D417/10
摘要： The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na+-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes related diseases such as an insulin-resistant diseases and obesity.
摘要翻译：本发明提供C-糖苷衍生物及其盐，其中B环通过-X-与A环键合，并且A环直接键合到葡萄糖残基，并且其可用作Na + 葡萄糖共转运蛋白抑制剂，特别是用于糖尿病的治疗和/或预防剂，例如胰岛素依赖性糖尿病（1型糖尿病）和不依赖胰岛素的糖尿病（2型糖尿病），以及糖尿病相关疾病如胰岛素抵抗疾病和肥胖。

12. 发明授权

US06903111B2 Isoquinuclidine derivative process for producing the same, and medicinal composition containing the same 失效
标题翻译：用于制备其的异奎宁环衍生物方法，以及含有它们的药物组合物
公开(公告)号：US06903111B2
公开(公告)日：2005-06-07
申请号：US10467719
申请日：2002-03-25
申请人： Hiroshi Tomiyama , Yoshinori Kobayashi , Atsushi Noda
发明人： Hiroshi Tomiyama , Yoshinori Kobayashi , Atsushi Noda
IPC分类号： A61P3/10 , C07D453/06 , A61K31/439
CPC分类号： C07D453/06
摘要： An isoquinuclidine derivative represented by the following general formula (I): (I) [wherein A1 is methylene or carbonyl]: R1 is hydrogen or methyl: R2 is —(CH2)n-A2-Ph (n is an integer of 0 to 3 and A2 is a single bond or —O—): and R3 is —COOH, —COOR4, —COSR4 (R4 is lower alkyl, unsubstituted phenyl, or phenyl substituted by a lower alkyl, lower alkoxy, hydroxyl, methoxycarbonyl, ethoxycarbonyl, or trifluoromethanesulfonamide group or by a halogen atom), etc.] or a pharmaceutically acceptable salt of the compound. Also provided is an oral remedy for diabetes, which contains the compound and has hypoglycemic activity.
摘要翻译：由以下通式（I）表示的异喹啉衍生物：（I）[其中A 1是亚甲基或羰基]：R 1是氢或甲基：R _{2 是 - （CH 2）2 - n - - - - - - - - - - （n是0至3的整数，A R 2是单键或-O-）：R 3是-COOH，-COOR 4，-COSR 4，（R 4）是低级烷基，未取代的苯基或被低级烷基，低级烷氧基，羟基，甲氧基羰基，乙氧基羰基或三氟甲磺酰胺基或卤素原子取代的苯基等）或该化合物的药学上可接受的盐。还提供了含有该化合物并具有降血糖活性的糖尿病口服补救剂。}

13. 发明申请

US20070161787A1 C-glycoside derivatives and salts thereof 有权
公开(公告)号：US20070161787A1
公开(公告)日：2007-07-12
申请号：US11710434
申请日：2007-02-26
申请人： Masakazu Imamura , Takeshi Murakami , Ryota Shiraki , Kazuhiro Ikegai , Takashi Sugane , Fumiyoshi Iwasaki , Eiji Kurosaki , Hiroshi Tomiyama , Atsushi Noda , Kayoko Kitta , Yoshinori Kobayashi
发明人： Masakazu Imamura , Takeshi Murakami , Ryota Shiraki , Kazuhiro Ikegai , Takashi Sugane , Fumiyoshi Iwasaki , Eiji Kurosaki , Hiroshi Tomiyama , Atsushi Noda , Kayoko Kitta , Yoshinori Kobayashi
IPC分类号： A61K31/7052 , C07H17/00
CPC分类号： C07D495/04 , A61K31/351 , A61K31/381 , A61K31/4035 , A61K31/404 , A61K31/41 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/4433 , A61K31/497 , A61K31/5377 , C07D405/10 , C07D407/10 , C07D409/10 , C07D413/10 , C07D417/10
摘要： The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na+-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes related diseases such as an insulin-resistant diseases and obesity.

14. 发明授权

US07045515B2 β-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same 有权
标题翻译：用于再现相同的β-内酰胺化合物的方法和含有它们的血清胆固醇降低剂
公开(公告)号：US07045515B2
公开(公告)日：2006-05-16
申请号：US10450171
申请日：2002-02-20
申请人： Hiroshi Tomiyama , Masayuki Yokota , Atsushi Noda , Akira Ohno
发明人： Hiroshi Tomiyama , Masayuki Yokota , Atsushi Noda , Akira Ohno
IPC分类号： C07D205/08 , A61K31/397 , A61P3/06
CPC分类号： C07D405/10 , C07D405/12
摘要： Novel β-lactam compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof which are useful as serum cholesterol-lowering agents: (I) wherein A1, A3 and A4 represent each hydrogen, halogen C1-5 alkyl, C1-5 alkoxy, —COOR1, a group represented by the following general formula (b): (b) wherein R1 represents hydrogen or C1-5 alkyl, or a group represented by the following general formula (a): (a) wherein R2 represents —CH2OH, —CH2OC(O)—R1 or —CO2—R1; R3 represents —OH or —OC(O)—R1; R4 represents —(CH2)kR5(CH2)1- wherein K and 1 are each 0 or an integer of 1 or above provided k+1 is an integer of not more than 10; and R5 represents a single bond, —CH═CH—, —OCH2—, carbonyl or —CH(OH)—; provided that at least one of A1, A3 and A4 is a group represented by the above formula (a); A2 represents C1-5 alkyl, C1-5 alkoxy, C1-5 alkenyl, C1-5 hydroxyalkyl or C1-5 carbonylalkyl; and n, p, q and r are each an integer of 0, 1 or 2.
摘要翻译：由下式（I）表示的新型β-内酰胺化合物或其药学上可接受的盐可用作血清降胆固醇剂：（I）其中A 1，A 3， >和A 4各自表示氢，卤素C 1-5烷基，C 1-5烷氧基，-COOR 1，（b）表示的基团：（b）其中R 1表示氢或C 1-5烷基，或由以下通式（b）表示的基团：以下通式（a）：（a）其中R 2代表-CH 2 OH，-CH 2 OC（O）-R' SUB> 1或-CO 2 -R 1; R 3表示-OH或-OC（O）-R 1; R 4表示 - （CH 2）2 R 5（CH 2）2 - （CH 2）其中K和1各自为0或1或更高的整数，k + 1为不大于10的整数; 和R 5表示单键，-CH-CH-，-OCH 2 - ，羰基或-CH（OH） - ; 条件是A 1，A 3和A 4中的至少一个是由上述式（a）表示的基团。 A 2表示C 1-5烷基，C 1-5烷氧基，C 1-5 - 烯基，C 1-5个羟基烷基或C 1-5烷基羰基; 并且n，p，q和r各自为0,1或2的整数。

15. 发明申请

US20090062527A1 Process for Preparing Optically Active Alcohols 有权
标题翻译：光学活性醇制备方法
公开(公告)号：US20090062527A1
公开(公告)日：2009-03-05
申请号：US12224098
申请日：2007-02-13
申请人： Hiroshi Tomiyama , Masayuki Yokota
发明人： Hiroshi Tomiyama , Masayuki Yokota
IPC分类号： C07D205/08 , C07D263/24 , C07C69/732
CPC分类号： C07D263/14 , C07B53/00 , C07B2200/07 , C07C67/31 , C07D205/08 , C07C69/732
摘要： This invention relates to a process for producing optically active alcohols using asymmetric reduction of aromatic ketones. This process gives optically active alcohols in high enantioselectivity at large scale production. Aromatic ketones represented by formula (I) [wherein, R1 are selected from hydrogen atom, halogen atom, lower alkyl group etc. R2 is —(CH2)n-R3 [wherein, n is 1 to 5 integer. R3 are selected from hydrogen atom, halogen atom, lower alkoxycarbonyl group etc. and formula (II) and (III). {wherein, R4 is selected from lower alkyl group (1 to 5 carbon atom) etc. R5 and R6 are the same or different and are selected from hydrogen atom, halogen atom, lower alkyl group etc.}]] are reduced by sodium borohydride, chlorotrimethylsilane and optically active 2-[bis(4-methoxyphenyl)hydroxymethyl]pyrrolidine represented by formula (IV) to give optically active alcohol represented by formula (V) stereoselectively. (wherein, R1 and R2 are as defined above.)
摘要翻译：本发明涉及使用芳族酮不对称还原制备光学活性醇的方法。该方法在大规模生产中提供高对映选择性的光学活性醇。由式（I）表示的芳族酮[其中，R 1选自氢原子，卤素原子，低级烷基等。R 2为 - （CH 2）n -R 3 [其中，n为1〜5的整数。 R3选自氢原子，卤素原子，低级烷氧基羰基等和式（II）和（III）。 {其中，R4选自低级烷基（1〜5个碳原子）等。R5和R6相同或不同，选自氢原子，卤素原子，低级烷基等}]]由硼氢化钠还原，氯代三甲基硅烷和由式（IV）表示的光学活性的2- [双（4-甲氧基苯基）羟甲基]吡咯烷，由式（Ⅴ）代表的光学活性醇立体选择地得到。（其中，R1和R2如上定义）

16. 发明申请

US20060154876A1 Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis 有权
标题翻译：血清胆固醇降低剂或动脉粥样硬化的预防或治疗剂
公开(公告)号：US20060154876A1
公开(公告)日：2006-07-13
申请号：US10560357
申请日：2004-06-15
申请人： Hiroshi Tomiyama , Masayuki Yokota , Kazuhiro Kosakai
发明人： Hiroshi Tomiyama , Masayuki Yokota , Kazuhiro Kosakai
IPC分类号： A61K31/7052 , A61K31/397 , A61K31/192
CPC分类号： C07D405/10 , A61K31/216 , A61K31/40 , A61K31/505 , A61K31/7052 , A61K2300/00
摘要： A serum cholesterol lowing agent or a preventive or therapeutile agent for atherosclerosis, which each comprises a combination of a compound represented by the following general formula (I) or pharmaceutical acceptable salts thereof with a cholesterol biosynthesis inhibitor and/or a fibrate type cholesterol lowing agent. (I) (b) (a) [In the formula, A1, A2, A3 and A4 each is hydrogen, a group represented by the formula (b), or a group represented by the formula (a), provided that at least one of these is a group represented by the formula (a); A2 is C1-5 alkyl etc; and n. p, q and r each is an integer of 0, 1 or 2.
摘要翻译：用于动脉粥样硬化的血清胆固醇降低剂或预防或治疗剂，其各自包含由以下通式（I）表示的化合物或其药学上可接受的盐与胆固醇生物合成抑制剂和/或贝特类胆固醇降低剂。（I）（b）（a）[式中，A 1，A 2，A 3，A 4，各自为氢，式（b）表示的基团或式（a）所示的基团，条件是它们中的至少一个为由式（a）表示的基团。 A 2是C 1-5烷基等; 和n。 p，q和r各自为0,1或2的整数。

17. 发明授权

US08358549B2 Semiconductor memory device, memory test method and computer program for designing program of semiconductor memory device 失效
标题翻译：半导体存储器件，存储器测试方法和用于设计半导体存储器件程序的计算机程序
公开(公告)号：US08358549B2
公开(公告)日：2013-01-22
申请号：US12788914
申请日：2010-05-27
申请人： Hiroshi Tomiyama
发明人： Hiroshi Tomiyama
IPC分类号： G11C7/00
CPC分类号： G11C29/16
摘要： A semiconductor memory device includes: a plurality of RAM macros; and a test control circuit configured to correlate the plurality of RAM macros with a plurality of memory test execution periods. The test control circuit outputs control signals to the plurality of RAM macros such that one RAM macro of the plurality of RAM macros is tested during one memory test execution period of the plurality of memory test execution periods, the one RAM macro being correlated with the one memory test execution period.
摘要翻译：半导体存储器件包括：多个RAM宏; 以及测试控制电路，被配置为将所述多个RAM宏与多个存储器测试执行周期相关联。测试控制电路向多个RAM宏输出控制信号，使得在多个存储器测试执行周期的一个存储器测试执行周期期间测试多个RAM宏中的一个RAM宏，一个RAM宏与一个RAM宏相关联内存测试执行周期。

18. 发明申请

US20120040968A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND 有权
标题翻译： DIAMINO杂环碳酰胺化合物
公开(公告)号：US20120040968A1
公开(公告)日：2012-02-16
申请号：US13266164
申请日：2010-05-06
申请人： Itsuro Shimada , Kazuo Kurosawa , Takahiro Matsuya , Kazuhiko Iikubo , Yutaka Kondoh , Akio Kamikawa , Hiroshi Tomiyama , Yoshinori Iwai
发明人： Itsuro Shimada , Kazuo Kurosawa , Takahiro Matsuya , Kazuhiko Iikubo , Yutaka Kondoh , Akio Kamikawa , Hiroshi Tomiyama , Yoshinori Iwai
IPC分类号： A61K31/497 , C07D405/14 , C07D401/14 , C07D491/113 , C07D403/12 , A61K31/551 , A61K31/538 , C07D409/14 , C07D417/12 , A61K31/55 , A61K31/541 , C07D471/08 , C07D241/28 , C07D401/12 , A61K31/513 , C07D239/48 , A61P35/00 , A61K31/5377
CPC分类号： C07D239/48 , C07D241/26 , C07D241/28 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/08 , C07D491/113
摘要： Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein.As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.
摘要翻译：提供了可用作抑制EML4-ALK融合蛋白的激酶活性的化合物。作为对具有针对EML4-ALK融合蛋白的激酶活性的抑制活性的化合物进行了深入和广泛的研究的结果，本发明人发现本发明的二氨基杂环羧酰胺化合物对EML4-ALK融合体的激酶活性具有抑制活性蛋白。通过这一发现，完成了本发明。本发明的化合物可以用作预防和/或治疗癌症的药物组合物，例如肺癌，非小细胞肺癌和小细胞肺癌。

19. 发明申请

US20080119441A1 Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia 失效
标题翻译：膦酸衍生物和相关高磷酸盐血症的治疗药物
公开(公告)号：US20080119441A1
公开(公告)日：2008-05-22
申请号：US11664830
申请日：2005-10-05
申请人： Hiroshi Tomiyama , Masayuki Yokota , Kazuo Tokuzaki , Ryoko Tomita
发明人： Hiroshi Tomiyama , Masayuki Yokota , Kazuo Tokuzaki , Ryoko Tomita
IPC分类号： A61K31/675 , A61K31/66 , C07F9/06 , C07F9/22
CPC分类号： C07F9/6541 , C07F9/3834 , C07F9/3882 , C07F9/3891 , C07F9/59 , C07F9/6539 , C07F9/65517 , C07F9/655345 , C07F9/655354 , C07F9/6558 , C07F9/65586
摘要： This invention related to a series of new phosphonic acid derivatives having anti-hyperphosphatemia activity. (I)[wherein: A is selected from —(CH2)n—, —CO—, —(CH2)n—CO—(CH2)m—, —(CH2)n—CS—(CH2)m— or branched alkylene group. B ring and C ring are selected from benzene ring, naphthalene ring, azulene ring or, heterocycle or fused heterocycle. D is —(CH2)(n+1)—, —(CH2)-O—(CH2)m—, —(CH2)—S(O)o—(CH2)m—, —CF3 or —(CH2)n—NR10—(CH2)m— (wherein: D ring is connected with the carbon atom composing C ring.) E is selected from oxygen atom or sulfur atom. P is phosphine atom. R1˜R7 (wherein R1 and R2, R4 and R5 are joined together with neighbored carbon atom to form 5˜7 membered saturated or unsaturated hydrocarbon ring, or 5˜6 membered fused heterocycle. R1, R2 and R3 are not hydrogen atom if B ring is benzene ring.) may be the same or different and are substituents. R8 and R9 are may be the same or different and are substituents. R10 is alkyl group. n and m are 0-10. o is 0-2.
摘要翻译：本发明涉及一系列具有抗高磷酸血症活性的新型膦酸衍生物。（I）[其中：A选自 - （CH 2）n - ， - CO - ， - （CH 2 H 2）（CH 2）n - ， - （CH 2）n - ， - （CH 2 CH 2）n - -C（ - ） - （CH 2 CH 2）m - 或支链亚烷基。 B环和C环选自苯环，萘环，薁环或杂环或稠合杂环。 D是 - （CH 2）2（n + 1） - ， - （CH 2）-O-（CH 2 CH 2）m - （CH 2） - （CH 2）n - （CH 2）m - / > - ， - CF 3 - 或 - （CH 2）n - NR 10 - （CH 3） 2）其中：D环与构成C环的碳原子连接。）E选自氧原子或硫原子。 P是膦原子。（其中R 1和R 2，R 4，R 4，R 4， R 5与邻位的碳原子连接在一起形成5〜7元饱和或不饱和烃环，或5〜6元稠合杂环，R 1，R 2， > 2和R 3不是氢原子，如果B环是苯环）可以相同或不同，并且是取代基。 R 8和R 9可以相同或不同，并且是取代基。 R 10是烷基。 n和m为0-10。 o是0-2。

20. 发明申请

US20070099956A1 Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl 失效
标题翻译：含2,6-二取代苯乙烯基的含氮杂环衍生物
公开(公告)号：US20070099956A1
公开(公告)日：2007-05-03
申请号：US10548197
申请日：2004-03-05
申请人： Kazumi Kikuchi , Makoto Oku , Jiro Fujiyasu , Norio Asai , Toshihiro Watana , Yukinori Nagakura , Hiroshi Tomiyama , Motoharu Sonegawa , Kazuo Tokuzaki , Yoshinori Iwai
发明人： Kazumi Kikuchi , Makoto Oku , Jiro Fujiyasu , Norio Asai , Toshihiro Watana , Yukinori Nagakura , Hiroshi Tomiyama , Motoharu Sonegawa , Kazuo Tokuzaki , Yoshinori Iwai
IPC分类号： A61K31/47 , A61K31/44 , C07D215/12 , C07D213/81
CPC分类号： C07D211/12
摘要： The invention provides a novel nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the nitrogen-containing heterocyclic derivative and a pharmaceutically acceptable salt thereof, in particular, a pharmaceutical composition effective as a sodium channel inhibitor, having an excellent analgesic action especially on neuropathic pain with minimized side effects.
摘要翻译：本发明提供了具有2,6-二取代苯乙烯基的新型含氮杂环衍生物及其药学上可接受的盐，以及包含含氮杂环衍生物及其药学上可接受的盐的药物组合物，特别是作为钠通道抑制剂，具有优异的镇痛作用，特别是对神经性疼痛具有最小的副作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式